Os fundamentos da empresa estão relativamente fraco(s). Sua avaliação é considerada avaliação justa,e o reconhecimento institucional é muito alto. Nos últimos 30 dias, diversos analistas classificaram a empresa como Comprar. Apesar de um desempenho muito fraco em bolsa, a empresa apresenta fundamentos sólidos. O preço das ações está oscilando entre suportes e resistências, cenário que favorece operações de swing trade em faixa.
Pontuação de Inotiv Inc
Informações relacionadas
Classificação
142 / 407
Classificação Geral
277 / 4616
Setor
Biotecnologia e Pesquisa Médica
Resistência e suporte
Sem dados
Gráfico de radar
Preço Atual
Anterior
Alvo dos analistas
Com base em um total de
3
analistas
Comprar
Classificação Atual
5.500
Preço-Alvo
+382.46%
Potencial de alta
Aviso: As classificações e preços-alvo dos analistas são fornecidos pela LSEG apenas para fins informativos e não constituem recomendação de investimento.
Destaques de Inotiv Inc
Pontos fortesRisco
Inotiv, Inc. is a contract research company, which is engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. The RMS segment offer access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
Sobreavaliada
O PE mais recente da empresa é -0.45, em uma faixa percentil alta de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 8.45M ações, uma redução de 30.46% em relação ao trimestre anterior.
Inotiv, Inc. is a contract research company, which is engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. The RMS segment offer access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.